GlassScriptPhysician profile
Shahriyar Tavakoli
NPI 1962407767
$13,841.70
in general payments reported to CMS, 2019-2025
42 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 78% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $212 · 2021: $893 · 2022: $997 · 2023: $8,929 · 2024: $1,251 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,117 · Food and Beverage: $4,389 · Travel and Lodging: $613 · Gift: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,117.33 |
| Food and Beverage | $4,388.79 |
| Travel and Lodging | $613.43 |
| Gift | $101.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,193.27 | 2022-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $633.23 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Insmed, INC. | $605.93 | 2019-2025 | Arikayce |
| Cumberland Pharmaceuticals, INC. | $604.01 | 2021-2024 | Vibativ |
| Inari Medical, INC. | $533.83 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| La Jolla Pharmaceutical Company | $428.76 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $373.15 | 2019-2025 | Zerbaxa, Winrevair, Keytruda |
| Astrazeneca Pharmaceuticals LP | $339.29 | 2019-2024 | Fasenra |
| Incyte Corporation | $248.77 | 2023-2024 | Monjuvi, Jakafi |
| Karyopharm Therapeutics INC. | $241.45 | 2023-2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.00 | 2020-2025 | Jascayd, Spiriva Respimat, Stiolto Respimat |
| Galvanize Therapeutics, INC | $157.55 | 2023 | Aliya System |
| Secura Bio, INC. | $153.71 | 2024 | Copiktra |
| Janssen Biotech, INC. | $150.00 | 2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $142.94 | 2022-2025 | Glassia |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $125.00 | 2023 | |
| Nevro Corp. | $124.78 | 2022 | |
| Amgen INC. | $123.13 | 2024 | Krystexxa |
| Grifols USA, LLC | $122.82 | 2021-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2025 | Dupixent |
| Stryker Corporation | $120.73 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Portola Pharmaceuticals, LLC | $118.44 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $116.48 | 2024 | Reblozyl |
| Tetraphase Pharmaceuticals, INC. | $113.64 | 2019 | |
| Pinnacle Biologics, INC | $109.34 | 2024 | Photofrin |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Biogen, INC. | $96.72 | 2021 | |
| Philips North America LLC | $62.86 | 2023-2025 | (8874) Incourage, Respiratory |
| Erbe USA INC | $50.00 | 2024 | |
| Mylan Specialty L.P. | $49.84 | 2019-2024 | Yupelri |
| Baxter Healthcare | $46.60 | 2025 | Hillrom - Volara System |
| Shionogi INC | $36.92 | 2024 | Fetroja |
| Actelion Pharmaceuticals US, INC. | $34.31 | 2023-2024 | Opsumit |
| Lilly USA, LLC | $23.05 | 2025 | Zepbound |
| Sunovion Pharmaceuticals INC. | $18.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.16 | 2025 | |
| Pulmonx Corporation | $16.50 | 2022 | |
| Pfizer INC. | $16.45 | 2025 | |
| Verona Pharma, INC. | $15.97 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $13.70 | 2020 | |
| Olympus America INC. | $12.11 | 2022 | |
| Itamar Medical INC | $8.93 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahriyar Tavakoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.